Please sign in so that we can notify you about a reply
Indications/Uses
Pregnancy: There have been reports of congenital anomalies (e.g., cleft palate and limb defects) in children of patients treated with Salbutamol. Some of the mothers, however, were receiving various medications in the course of their pregnancies. Since there is no consistent pattern of congenital abnormality development, a relationship between the use of Salbutamol and the development of congenital anomalies cannot be established. Therefore, Salbutamol should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus.
Lactation: Salbutamol may be secreted in breast milk. Therfore, do not administer to the breastfeeding women unless, in the opinion of a physician, the potential benefits of the drug justify the possible risk to the baby.
Lactation: Salbutamol may be secreted in breast milk. Therfore, do not administer to the breastfeeding women unless, in the opinion of a physician, the potential benefits of the drug justify the possible risk to the baby.
Dosage/Direction for Use
See table.
Overdosage
Symptoms of Salbutamol overdose include extensions of the common undesirable effects (e.g., tremor, nervousness, headache, dizziness, sleeplessness or insomnia, hypertension or hypotension, palpitation, tachycardia, arrhythmia, angina, dry mouth, and nausea). Hypokalemia has also been reported; thus, plasma potassium concentrations should be monitored.
Discontinue Salbutamol and institute appropriate symptomatic therapy in cases of Salbutamol overdosage. Administration of a beta-adrenergic blocking agent may be appropriate, but use with caution if the patient is asthmatic. There is no adequate evidence to support the use of dialysis in the treatment of Salbutamol overdose.
Discontinue Salbutamol and institute appropriate symptomatic therapy in cases of Salbutamol overdosage. Administration of a beta-adrenergic blocking agent may be appropriate, but use with caution if the patient is asthmatic. There is no adequate evidence to support the use of dialysis in the treatment of Salbutamol overdose.
Administration
Should be taken on an empty stomach: Take 1 hr before or 2 hr after meals.
Special Precautions
If a previously effective dose fails to provide the usual relief or the usual duration of effect is reduced, consult a physician for medical advice as this may be a sign of worsening of asthma that would require reassessment of therapy.
Paradoxical bronchospasm, a pontentially life-threatening event, may occur with the administration of oral Salbutamol. If it occurs, discontinue use of the product immediately.
Use with caution in acute severe asthma where concomitant therapy with steroids, xanthine derivatives, or diuretics, and by hypoxia may result in hypokalemia; plasma potassium concentrations should be monitored in severe asthma.
Treatment with Salbutamol and other beta2-agonists may decrease plasma potassium concentration possibly through intracellular shunting resulting in cardiovascular adverse effects.
Use with caution in patients with the following conditions: Cardiovascular disorders including coronary sufficiency, cardiac arrhythmias or hypertension; Convulsive disorders; Hyperthyroidism; Diabetes mellitus; In patients who are unusually responsive to synpathomimetic amines.
Paradoxical bronchospasm, a pontentially life-threatening event, may occur with the administration of oral Salbutamol. If it occurs, discontinue use of the product immediately.
Use with caution in acute severe asthma where concomitant therapy with steroids, xanthine derivatives, or diuretics, and by hypoxia may result in hypokalemia; plasma potassium concentrations should be monitored in severe asthma.
Treatment with Salbutamol and other beta2-agonists may decrease plasma potassium concentration possibly through intracellular shunting resulting in cardiovascular adverse effects.
Use with caution in patients with the following conditions: Cardiovascular disorders including coronary sufficiency, cardiac arrhythmias or hypertension; Convulsive disorders; Hyperthyroidism; Diabetes mellitus; In patients who are unusually responsive to synpathomimetic amines.
Use In Pregnancy & Lactation
Pregnancy: There have been reports of congenital anomalies (e.g., cleft palate and limb defects) in children of patients treated with Salbutamol. Some of the mothers, however, were receiving various medications in the course of their pregnancies. Since there is no consistent pattern of congenital abnormality development, a relationship between the use of Salbutamol and the development of congenital anomalies cannot be established. Therefore, Salbutamol should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus.
Lactation: Salbutamol may be secreted in breast milk. Therfore, do not administer to the breastfeeding women unless, in the opinion of a physician, the potential benefits of the drug justify the possible risk to the baby.
Lactation: Salbutamol may be secreted in breast milk. Therfore, do not administer to the breastfeeding women unless, in the opinion of a physician, the potential benefits of the drug justify the possible risk to the baby.
Adverse Reactions
The most frequent adverse reactions of oral Salbutamol include tremors (particularly the hands), nervousness, headache, dizziness, sleeplessness or insomnia, weakness, drowsiness, restlessness, irritability, tachcardia, palpitation, peripheral vasodilation, flushing, chest discomfort, nausea, dyspepsia, difficulty in micturition, and rarely muscle cramps.
Erythema multiforme or Stevens-Johnson syndrome has been reported rarely with administration of oral Salbutamol in children.
Potentially serious hypokalemia has also been reported.
Hypersensitivity reactions (including urticaria, angioedema, rash, paradoxical bronchospasm, anaphylaxis, oropharyngeal edema, and collapse) and arrhythmias (including atrial fibrillation, supraventricular tachycardia, and extrasystoles) have been observed with the use of Salbutamol.
Salbutamol, like other sympathomimetic agents, can cause vertigo, central nervous system stimulation, angina, hypertension, unusual taste, and drying and irritation of the oropharynx.
Erythema multiforme or Stevens-Johnson syndrome has been reported rarely with administration of oral Salbutamol in children.
Potentially serious hypokalemia has also been reported.
Hypersensitivity reactions (including urticaria, angioedema, rash, paradoxical bronchospasm, anaphylaxis, oropharyngeal edema, and collapse) and arrhythmias (including atrial fibrillation, supraventricular tachycardia, and extrasystoles) have been observed with the use of Salbutamol.
Salbutamol, like other sympathomimetic agents, can cause vertigo, central nervous system stimulation, angina, hypertension, unusual taste, and drying and irritation of the oropharynx.
Drug Interactions
Do not use with other oral sympathomimetic bronchodilators or Epinephrine to avoid deleterious cardiovascular effects.
Concurrent administration with monoamine oxidase (MAO) inhibitors or tricyclic antidepressants may increase the risk of cardiac arrhythmia, tachycardia and increased or decreased blood pressure.
Do not administer with beta-blockers since these agents inhibit Salbutamol's effect.
Concurrent administration with monoamine oxidase (MAO) inhibitors or tricyclic antidepressants may increase the risk of cardiac arrhythmia, tachycardia and increased or decreased blood pressure.
Do not administer with beta-blockers since these agents inhibit Salbutamol's effect.
Storage
Store at temperatures not exceeding 30°C.
Action
Pharmacology: Pharmacodynamics: Salbutamol is a selective short-acting beta2-adrenergic agonist with preferential effect on beta2-adrenergic receptors in the respiratory tract. It stimulates adenyl cyclase, the enzyme which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP); cAMP mediates cellular responses such as bronchial smooth muscle relaxation resulting in bronchodilation.
Pharmacokinetics: Salbutamol is readily absorbed from the gastrointestinal tract after oral administration. Salbutamol's onset of action is within 30 minutes, peaks in 2 to 3 hours and persists for 4 to 6 hours after a dose; the plasma half-life of is from 4-6 hours. It is extensively metabolized in the liver, being converted to salbutamol 4'-O-sulfate. Salbutamol and its metabolites are rapidly excreted in urine and feces. After oral administration of Salbutamol to healthy individuals, about 75% of a single dose is excreted in urine within 72 hours, mainly as the major metabolite about 4% of the dose is excreted in feces.
Animal studies show that Salbutamol can cross the blood-brain barrier and the placenta. It may be secreted in breast milk, but concentrations are not known.
Pharmacokinetics: Salbutamol is readily absorbed from the gastrointestinal tract after oral administration. Salbutamol's onset of action is within 30 minutes, peaks in 2 to 3 hours and persists for 4 to 6 hours after a dose; the plasma half-life of is from 4-6 hours. It is extensively metabolized in the liver, being converted to salbutamol 4'-O-sulfate. Salbutamol and its metabolites are rapidly excreted in urine and feces. After oral administration of Salbutamol to healthy individuals, about 75% of a single dose is excreted in urine within 72 hours, mainly as the major metabolite about 4% of the dose is excreted in feces.
Animal studies show that Salbutamol can cross the blood-brain barrier and the placenta. It may be secreted in breast milk, but concentrations are not known.
MedsGo Class
Antiasthmatic & COPD Preparations
Features
Dosage
2mg
Ingredients
- Salbutamol
Packaging
Tablet 100's
Generic Name
Salbutamol
Registration Number
DR-XY27633
Classification
Prescription Drug (RX)
Product Questions
Questions
